MYCN and neuroblastoma: In contrast, MYCN-amplified cells were particularly sensitive to RTA-408 treatment, as evidenced by an inhibition rate of 93.2% ± 11.0% (Figure 6C), suggesting that RTA-408 shows pronounced therapeutic selectivity and potency in neuroblastoma cells driven by Myc.